In the face of ineffective vaccines, increasing antibiotic resistance and the decline in new
antibacterial drugs in the pipeline, tuberculosis (TB) still remains pandemic. Exposure to …

Introduction The Bacillus Calmette-Guérin (BCG) vaccine, currently used against
tuberculosis (TB), exhibits inconsistent efficacy, highlighting the need for more potent TB …

Six of the top ten leading causes of death in low resource settings could potentially be
prevented by vaccination. Development of vaccines for individuals in these populations is …

Tuberculosis (TB) is a leading cause of death globally. Understanding the population
dynamics of TB's causative agent Mycobacterium tuberculosis complex (Mtbc) in-host is vital …

Mycobacterium tuberculosis–specific (M. tuberculosis–specific) T cell responses associated
with immune control during asymptomatic latent tuberculosis infection (LTBI) remain poorly …

Background Most individuals developing tuberculosis (TB) are working age adults living in
low-and middle-income countries (LMICs). The resulting disability and death impact …

The development of effective vaccines against bacterial lung infections requires the
induction of protective, pathogen-specific immune responses without deleterious …

Tuberculosis (TB), also known as the “White Plague”, is caused by Mycobacterium
tuberculosis (Mtb). Before the COVID-19 epidemic, TB had the highest mortality rate of any …

Abstract The Bacille Calmette Guérin (BCG) vaccine was developed over a century ago and
has become one of the most used vaccines without undergoing a modern vaccine …

Mycobacterium tuberculosis has thrived in parallel with humans for millennia, and despite
our efforts, M. tuberculosis continues to plague us, currently infecting a third of the world's …